LLY

808.07

0%↓

JNJ

155.14

-0.84%↓

ABBV

191.24

+0.99%↑

NVO

78.61

-0.99%↓

UNH

310.49

+2.21%↑

LLY

808.07

0%↓

JNJ

155.14

-0.84%↓

ABBV

191.24

+0.99%↑

NVO

78.61

-0.99%↓

UNH

310.49

+2.21%↑

LLY

808.07

0%↓

JNJ

155.14

-0.84%↓

ABBV

191.24

+0.99%↑

NVO

78.61

-0.99%↓

UNH

310.49

+2.21%↑

LLY

808.07

0%↓

JNJ

155.14

-0.84%↓

ABBV

191.24

+0.99%↑

NVO

78.61

-0.99%↓

UNH

310.49

+2.21%↑

LLY

808.07

0%↓

JNJ

155.14

-0.84%↓

ABBV

191.24

+0.99%↑

NVO

78.61

-0.99%↓

UNH

310.49

+2.21%↑

Search

Axsome Therapeutics Inc

Închisă

SectorSănătate

108.04 -1.66

Rezumat

Modificarea prețului

24h

Curent

Minim

107.52

Maxim

111

Indicatori cheie

By Trading Economics

Venit

15M

-59M

Vânzări

2.7M

121M

EPS

-1.216

Marjă de profit

-48.914

Angajați

712

EBITDA

14M

-57M

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+63.56% upside

Dividende

By Dow Jones

Următoarele câștiguri

4 aug. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

-62M

5.4B

Deschiderea anterioară

109.7

Închiderea anterioară

108.04

Sentimentul știrilor

By Acuity

24%

76%

50 / 380 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Weak Bearish Evidence

Axsome Therapeutics Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

11 iun. 2025, 22:03 UTC

Principalele dinamici ale pieței

Gamestop Shares Fall After Company Plans Convertible Notes Offering

11 iun. 2025, 20:51 UTC

Câștiguri

Oracle Shares Jump as CEO Targets 'Dramatically Higher' Revenue Growth Ahead

11 iun. 2025, 23:46 UTC

Market Talk

Nikkei May Decline on Tariff Uncertainty, Stronger Yen -- Market Talk

11 iun. 2025, 23:39 UTC

Market Talk

Gold Edges Higher Amid Geopolitical Tensions -- Market Talk

11 iun. 2025, 22:16 UTC

Câștiguri

Oracle Shares Jump With Target for Major Revenue Gains Ahead -- Update

11 iun. 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

11 iun. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

11 iun. 2025, 20:27 UTC

Câștiguri

Chime Gets Set to Debut as IPO Market Starts to Heat Up -- Barrons.com

11 iun. 2025, 20:27 UTC

Câștiguri

These Stocks Moved the Most Today: Tesla, Cleveland-Cliffs, Quantum Computing, Oklo, SailPoint, Lockheed, and More -- Barrons.com

11 iun. 2025, 20:10 UTC

Câștiguri

Oracle Expects Triple-Digit MultiCloud Rev Growth to Continue in FY26 >ORCL

11 iun. 2025, 20:09 UTC

Câștiguri

Oracle: Cloud Infrastructure Growth Rate Is Expected to Increase From 50% in FY25 to Over 70% in FY26 >ORCL

11 iun. 2025, 20:08 UTC

Câștiguri

Oracle Expects Total Cloud Growth Rate--Applications Plus Infrastructure--Will Increase From 24% in FY25 to Over 40% in FY26 >ORCL

11 iun. 2025, 20:08 UTC

Câștiguri

Oracle Sees Revenue Growth Rates 'Dramatically Higher' in FY26 >ORCL

11 iun. 2025, 20:08 UTC

Câștiguri

Oracle 4Q Non-GAAP Operating Income Was $7 B >ORCL

11 iun. 2025, 20:08 UTC

Câștiguri

Oracle 4Q GAAP Operating Income Was $5.1 B >ORCL

11 iun. 2025, 20:08 UTC

Câștiguri

Oracle 4Q Remaining Performance Obligations $138 B >ORCL

11 iun. 2025, 20:05 UTC

Câștiguri

Oracle 4Q Rev $15.9B >ORCL

11 iun. 2025, 20:05 UTC

Câștiguri

Oracle 4Q Hardware Revenue $850M >ORCL

11 iun. 2025, 20:05 UTC

Câștiguri

Oracle 4Q Net $3.4B >ORCL

11 iun. 2025, 20:05 UTC

Câștiguri

Oracle 4Q Services Revenue $1.35B >ORCL

11 iun. 2025, 20:05 UTC

Câștiguri

Oracle 4Q Adj EPS $1.70 >ORCL

11 iun. 2025, 20:05 UTC

Câștiguri

Oracle 4Q Cloud License and On-Premise License Revenue $2.01B >ORCL

11 iun. 2025, 20:05 UTC

Câștiguri

Oracle 4Q EPS $1.19 >ORCL

11 iun. 2025, 20:05 UTC

Câștiguri

Oracle 4Q Cloud Services and License Support Revenue $11.7B >ORCL

11 iun. 2025, 19:00 UTC

Market Talk

Oil Futures Soar on Raft of Supportive News -- Market Talk

11 iun. 2025, 18:55 UTC

Market Talk

U.S. Natural Gas Futures Slip Ahead of Storage Data -- Market Talk

11 iun. 2025, 18:49 UTC

Câștiguri

These Stocks Are Moving the Most Today: Tesla, Cleveland-Cliffs, Quantum Computing, Oklo, SailPoint, Lockheed, and More -- Barrons.com

11 iun. 2025, 18:22 UTC

Market Talk

Gold Flat After Tentative U.S.-China Trade Deal -- Market Talk

11 iun. 2025, 18:19 UTC

Market Talk

UnitedHealth Seen on Longer Road to Recovery -- Market Talk

11 iun. 2025, 18:08 UTC

Market Talk
Câștiguri

Vera Bradley Leans on Retail Partnerships to Drive Engagement -- Market Talk

Comparație

Modificare preț

Axsome Therapeutics Inc Așteptări

Obiectiv de preț

By TipRanks

63.56% sus

Prognoză pe 12 luni

Medie 179.77 USD  63.56%

Maxim 210 USD

Minim 148 USD

În baza a 16 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruAxsome Therapeutics Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

16 ratings

16

Cumpărare

0

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

107.24 / 112.29Suport & Rezistență

Termen scurt

Weak Bearish Evidence

Termen mediu

Neutral Evidence

Termen lung

Strong Bullish Evidence

Sentiment

By Acuity

50 / 380 Clasament în Sănătate

Sentimentul știrilor

Evidențe foarte puternice de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Peste medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Axsome Therapeutics Inc

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.